Jazz Pharmaceuticals (NASDAQ:JAZZ) Lifted to “Hold” at BidaskClub

BidaskClub upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a sell rating to a hold rating in a report issued on Thursday morning, BidAskClub reports.

Other equities analysts have also issued research reports about the company. HC Wainwright set a $12.00 target price on IMV and gave the stock a buy rating in a research note on Friday, May 10th. Royal Bank of Canada set a $184.00 target price on Jazz Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, July 3rd. Zacks Investment Research lowered GALP ENERGIA SG/ADR from a hold rating to a sell rating in a research note on Monday, May 6th. Oppenheimer set a $176.00 target price on Jazz Pharmaceuticals and gave the stock a buy rating in a research note on Monday, July 8th. Finally, Piper Jaffray Companies set a $202.00 target price on Jazz Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, May 28th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the company’s stock. Jazz Pharmaceuticals presently has an average rating of Buy and a consensus price target of $179.41.

Shares of Jazz Pharmaceuticals stock opened at $136.62 on Thursday. Jazz Pharmaceuticals has a 52 week low of $113.52 and a 52 week high of $181.46. The company has a fifty day simple moving average of $134.77. The firm has a market cap of $7.74 billion, a price-to-earnings ratio of 10.61, a PEG ratio of 1.14 and a beta of 1.15. The company has a current ratio of 3.15, a quick ratio of 3.01 and a debt-to-equity ratio of 0.63.



Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.83 by $0.44. Jazz Pharmaceuticals had a return on equity of 27.35% and a net margin of 24.88%. The business had revenue of $508.19 million for the quarter, compared to analyst estimates of $466.55 million. During the same quarter in the prior year, the company posted $2.98 EPS. The company’s quarterly revenue was up 14.3% on a year-over-year basis. On average, research analysts expect that Jazz Pharmaceuticals will post 13.23 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of JAZZ. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in Jazz Pharmaceuticals during the 1st quarter worth about $25,000. Prime Capital Investment Advisors LLC purchased a new stake in Jazz Pharmaceuticals during the 1st quarter worth about $27,000. Carroll Financial Associates Inc. increased its holdings in Jazz Pharmaceuticals by 166.7% during the 1st quarter. Carroll Financial Associates Inc. now owns 200 shares of the specialty pharmaceutical company’s stock worth $28,000 after purchasing an additional 125 shares during the period. Machina Capital S.A.S. purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter worth about $29,000. Finally, Osborn Williams & Donohoe LLC purchased a new stake in Jazz Pharmaceuticals during the 1st quarter worth about $33,000. Institutional investors own 89.81% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: Technical Analysis of Stocks and What It Means

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.